Flow Pharma, Inc. and OncoImmunity AS partner for the Development of FlowVaxTM Personalized Cancer Vaccines

67

OSLO, Norway–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/neoantigen?src=hash" target="_blank"gt;#neoantigenlt;/agt;–Flow Pharma Inc., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, today announced a collaboration with Norwegian bioinformatics company OncoImmunity AS. Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform. The Immuneoprofiler™ has recently received the CE-IVD mark certification http://www.businesswire.com/news/home/20190312005768/en/Flow-Pharma-OncoImmunity-partner-Development-FlowVaxTM-Personalized/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==